The Vitamin B9 market in the United States is expected to remain under mild downward pressure during the first half of July 2026 as comfortable inventories, balanced supply-demand conditions, and stable production continue to limit price recovery. During June, Vitamin B9 prices remained largely unchanged on a weekly basis despite recording a modest monthly decline of 0.48%, reflecting the broader 12-week bearish trend. Demand from the nutrition, dietary supplement, pharmaceutical, and food-fortification sectors remained steady, with buyers maintaining routine procurement and avoiding aggressive purchasing. On the supply side, uninterrupted manufacturing operations, stable feedstock costs, and adequate inventories ensured consistent product availability, preventing significant price volatility. Weekly assessments described the Vitamin B9 market as calm and balanced, with limited spot trading and orderly negotiations. Looking forward, Vitamin B9 prices are anticipated to ease further in early July unless stronger downstream demand or unexpected supply disruptions emerge. Market participants will continue monitoring inventory levels, upstream cost movements, and procurement activity across key end-use sectors, while the Vitamin B9 market is expected to remain broadly stable under prevailing bearish fundamentals.
Vitamin B9 prices in the United States are anticipated to ease further during the first half of July 2026, as ample product availability, balanced supply-demand fundamentals, and comfortable inventory levels continue to weigh on market sentiment. With no major supply disruptions or significant improvement in downstream purchasing expected, buyers are likely to maintain cautious procurement strategies, keeping upward price momentum limited. The Vitamin B9 market is therefore expected to remain under mild bearish pressure before any meaningful recovery depends on stronger demand from the pharmaceutical, nutrition, or food-fortification sectors.
Vitamin B9 prices in the USA were effectively flat through late June 2026 even as the month closed with a small monthly decline, reflecting a calm spot market and balanced fundamentals. Early June saw unchanged trading, and the pattern persisted into mid- and late June as market participants reported balanced supply-demand conditions and steady input costs. Nevertheless, on a month-on-month basis, Vitamin B9 prices decreased by 0.48% during June 2026, according to ChemAnalyst data. This modest decline came against a broader 12-week bearish trend in moving averages while weekly spot levels remained stable.
Demand-side dynamics for Vitamin B9 showed no clear pockets of strength or sudden weakness during the month. The nutrition and dietary supplement sectors maintained steady purchasing, while pharmaceutical and food-fortification customers also continued routine procurement without significant changes in buying volumes. Unlike more volatile specialty ingredient markets, Vitamin B9 consumption remained well balanced throughout June. The absence of stronger offtake prevented any notable price recovery, allowing the longer-term bearish trend to persist despite steady weekly trading activity.
On the supply side, the Vitamin B9 market remained well supplied, with production operating smoothly and placing no upward pressure on prices. Market participants cited balanced supply-demand conditions across the value chain and stable upstream feedstock and energy costs. No major plant shutdowns or maintenance activities were reported at key manufacturing facilities, while distributors maintained comfortable inventories. These factors ensured uninterrupted availability of Vitamin B9 and supported the market's stable weekly performance.
Weekly assessments indicated that Vitamin B9 prices remained largely unchanged across early, mid, and late June, with trading activity consistently described as calm and orderly. Buyers focused on routine contractual purchases rather than aggressive spot procurement, while sellers showed limited urgency to adjust offers. Although weekly prices remained stable, the broader 12-week moving average continued to signal underlying bearish market sentiment.
Looking ahead, analysts expect the Vitamin B9 market to remain sensitive to the ongoing bearish trend and any changes in upstream costs or downstream demand. Continued balanced supply-demand conditions and stable production are likely to keep Vitamin B9 prices under mild pressure through early July, with any sustained recovery depending on stronger demand or tighter supply conditions later in the quarter.
